-
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data
Noteboom, S., Strijbis, E. M. M., Coerver, E. M. E., Colato, E., van Kempen, Z. L. E., Jasperse, B., Vrenken, H., Killestein, J., Schoonheim, M. M. & Steenwijk, M. D., Jul 2024, In: Multiple Sclerosis and Related Disorders. 87, 105670.Research output: Contribution to journal › Article › Academic › peer-review
-
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time
Bouman, P. M., van Dam, M. A., Jonkman, L. E., Steenwijk, M. D., Schoonheim, M. M., Geurts, J. J. G. & Hulst, H. E., May 2024, In: Journal of neurology. 271, 5, p. 2159-2168 10 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
Toorop, A. A., Noteboom, S., Steenwijk, M. D., Gravendeel, J. W., Jasperse, B., Barkhof, F., Strijbis, E. M. M., Rispens, T., Schoonheim, M. M., van Kempen, Z. L. E. & Killestein, J., Feb 2024, In: MULTIPLE SCLEROSIS JOURNAL. 30, 2, p. 266-271 6 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
